Moderna Inc MRNA shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
The results showed that mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) versus Keytruda alone for the adjuvant treatment of stage III/IV melanoma following complete resection...Read More
See Also: Moderna Soars On Cancer Vaccine News: Here's What To Watch Going Forward
According to data from Benzinga Pro, MRNA has a 52-week high of $321.30 and a 52-week low of $115.03.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
